title: TOLERANCE OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN PATIENTS WITH OCULAR HYPERTENSION OR OPEN-ANGLE GLAUCOMA.
abstract: OBJECTIVE
  Evaluate the pressure tolerance of dexamethasone implants in open-angle glaucoma (OAG+) patients and ocular hypertension (OHT+) patients compared with nonglaucomatous and nonhypertensive patients.
  
  
  METHODS
  Retrospective observational 2-center, controlled study including 100 patients treated with intravitreal injections of dexamethasone, divided into 2 groups: Group 1, OAG+/OHT+ (n = 50), and Group 2, OAG-/OHT- (n = 50), matched for age and disease. Intraocular pressure (IOP) and hypotensive treatment were evaluated initially, at 8 days, and every month for 6 months after intravitreal treatment. The primary endpoint was IOP increase greater than 10 mmHg.
  
  
  RESULTS
  Thirty-four percent of glaucomatous patients experienced a transient IOP increase greater than 10 mmHg versus 16% in the OAG-/OHT- group (P = 0.06). Intraocular pressure greater than 25 mmHg was recorded early on Day 8 in 6% of the OAG+ patients versus 2% of the OAG- patients. Fifty-four percent of the glaucoma patients increased their treatment, and hypotensive treatment was initiated in 38% of the OAG- patients (P = 0.1). Filtering surgery was only required in the OAG+/OHT+ group (6% versus 0%), particularly in dual-therapy and triple-therapy patients, who had a higher risk of filtering surgery (P = 0.008).
  
  
  CONCLUSIONS
  Half of the OAG+ and OHT+ patients needed an add-on treatment, with early onset beginning on Day 8 in 6%. This emphasizes the need for IOP monitoring during treatment, especially for OAG+/OHT+ patients.
authors.affiliation: *Ophthalmology, Croix-Rousse University Hospital, Lyon, France; †Ophthalmology, Desgenettes Military Hospital, Lyon, France; and ‡Ezus Lyon, Biostatistique, Lyon, France.
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Vié
authors.forename: Laurent
authors.initials: L
authors.lastname: Kodjikian
authors.forename: Ariane
authors.initials: A
authors.lastname: Malclès
authors.forename: Emilie
authors.initials: E
authors.lastname: Agard
authors.forename: Nicolas
authors.initials: N
authors.lastname: Voirin
authors.forename: Hussam
authors.initials: H
authors.lastname: El Chehab
authors.forename: Anh-Minh
authors.initials: AM
authors.lastname: Nguyen
authors.forename: Corinne
authors.initials: C
authors.lastname: Dot
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003692:Delayed-Action Preparations; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D014794:Visual Fields
chemical_list: D003692:Delayed-Action Preparations; D004343:Drug Implants; D003907:Dexamethasone